Research ArticlePsoriatic Arthritis
Open Access
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon and Josef S. Smolen
The Journal of Rheumatology July 2022, 49 (7) 694-699; DOI: https://doi.org/10.3899/jrheum.210906
Philip J. Mease
1P.J. Mease, MD, Swedish Medical Center/Providence St.Joseph Health and University of Washington School of Medicine, Seattle, Washington, USA;
Arthur Kavanaugh
2A. Kavanaugh, MD, University of California, San Diego, School of Medicine, La Jolla, California, USA;
Alexis Ogdie
3A. Ogdie, MD, University of Pennsylvania, Philadelphia, Pennsylvania, USA;
Alvin F. Wells
4A.F. Wells, MD, PhD, Aurora Rheumatology and Immunotherapy Center, Franklin, Wisconsin, USA;
Martin Bergman
5M. Bergman, MD, Drexel University College of Medicine, Philadelphia, Pennsylvania, USA;
Dafna D. Gladman
6D.D. Gladman, MD, Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada;
Sven Richter
7S. Richter, MD, L. Teng, PhD, S.Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA;
Lichen Teng
7S. Richter, MD, L. Teng, PhD, S.Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA;
Shauna Jardon
7S. Richter, MD, L. Teng, PhD, S.Jardon, PharmD, Amgen Inc., Thousand Oaks, California, USA;
Josef S. Smolen
8J.S. Smolen, MD, Medical University of Vienna, Austria.
REFERENCES
- 1.↵
- 2.↵
- Kavanaugh A,
- Gladman DD,
- Edwards CJ, et al.
- 3.↵Otezla [package insert]. Thousand Oaks, CA: Amgen, Inc.; 2020.
- 4.↵
- Kavanaugh A,
- Mease PJ,
- Gomez-Reino JJ, et al.
- 5.↵
- Cutolo M,
- Myerson GE,
- Fleischmann R, et al.
- 6.↵
- Edwards CJ,
- Blanco FJ,
- Crowley J, et al.
- 7.↵
- 8.↵
- 9.↵
- Haroon M,
- Gallagher P,
- FitzGerald O.
- 10.↵
- Theander E,
- Husmark T,
- Alenius GM, et al.
- 11.↵
- Gossec L,
- Baraliakos X,
- Kerschbaumer A, et al.
- 12.↵
- Mease PJ,
- Gladman DD,
- Ogdie A, et al.
- 13.↵
- 14.↵
- Smolen JS,
- Schols M,
- Braun J, et al.
- 15.↵
- 16.↵
- Shafran IH,
- Alasti F,
- Smolen JS,
- Aletaha D.
- 17.↵
- Mease PJ.
In this issue
The Journal of Rheumatology
Vol. 49, Issue 7
1 Jul 2022
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S. Smolen
The Journal of Rheumatology Jul 2022, 49 (7) 694-699; DOI: 10.3899/jrheum.210906
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Philip J. Mease, Arthur Kavanaugh, Alexis Ogdie, Alvin F. Wells, Martin Bergman, Dafna D. Gladman, Sven Richter, Lichen Teng, Shauna Jardon, Josef S. Smolen
The Journal of Rheumatology Jul 2022, 49 (7) 694-699; DOI: 10.3899/jrheum.210906